Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. L.A. (Lisa) de Jong

dr. L.A. (Lisa) de Jong

Postdoctoral Researcher Global Health Economics
Profile picture of dr. L.A. (Lisa) de Jong
E-mail:
l.a.de.jong rug.nl

Research interests

Lisa has a background in pharmacy and conducted her doctoral research 'Health economics of direct oral anticoagulants in the Netherlands' at the department of Pharmacotherapy, -epidemiology, and -economics — University of Groningen. Her research focusses on health economic modelling for reimbursement and clinical decision-making purposes, with special interest in using real-world data to populate models and expertise in cardiorenal metabolic diseases. Currently, Lisa is involved in various research projects and technical appraisals for the National Institute for Health and Care Excellence in the UK. Expertise: pharmacoeconomics, health economics, burden of disease, budget impact, health technology assessment, cost-effectiveness.

Publications

Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead

Lung cancer screening with volume computed tomography is cost-effective in Greece

A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?

Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis

Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data

Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran

Cost-Effectiveness Models of Continuous Glucose Monitoring in Individuals With Type 1 Diabetes: A Systematic Review on Methodology and Quality